BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$26.18 USD
-0.77 (-2.86%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.46 +0.28 (1.07%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
BridgeBio Pharma, Inc. [BBIO]
Reports for Purchase
Showing records 21 - 39 ( 39 total )
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Acoramidis Phase 3 Trial Misses Primary Endpoint; Lowering PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Recent Approvals Validate Approach; R&D Day Showcase; Raising PT to $88
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Oncology Pipeline Appears Underrated; Raising PT to $87
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
The Bugs for Your Gut: Takeaways from the Recent Autism Spectrum Disorders Symposium
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Cardiovascular Disease Precision Medicine Collaboration; Raising PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Infigratinib New Drug Application Accepted for FDA Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
BBP-398 Advancing Towards Clinic; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
High-Profile Academic Institution Collaborations Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Eidos Merger Agreement; Another Orphan Designation; Raising PT to $53
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Fosdenopterin Filing Accepted; R-D Day Pipeline Showcase; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Orphan Drug Status Granted to Portfolio Company; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
China Deal Inked With LianBio; 2Q20 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
QED Therapeutics Starts Phase 2 Achondroplasia Trial Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Phoenix Tissue Repair BBP-589 Poster Presentation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
BBP-418 Patient Dosing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
1Q20 Financials Reported; Pipeline Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
Infigratinib Preclinical Results Support Low Dose in Achondroplasia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BridgeBio Pharma, Inc.
Industry: Medical - Generic Drugs
A Burgeoning Colossus in Niche Disorders; Initiating at Buy and $50 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R